Research Topics
| P L OlliaroSummaryAffiliation: World Health Organization Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A reviewP L Olliaro
UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, CH 1211 Geneva 27, Switzerland
J Postgrad Med 50:40-4. 2004..This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin based combinations to those that need them most...
Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western SenegalPhilippe Brasseur
UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, 20 Avenue Appia, Geneva 27, CH, 1211, Switzerland
Malar J 11:402. 2012..abstract:..- Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan AfricaJulien Zwang
Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
Malar J 11:260. 2012..The widespread use of artesunate-amodiaquine (ASAQ) for treating uncomplicated malaria makes it important to gather and analyse information on its tolerability... - Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan AfricaJulien Zwang
Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
Malar J 11:25. 2012..A comprehensive appreciation of its effects on haematology vs other anti-malarials is needed in view of potential safety liabilities... - Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trialDorothee Heemskerk
Hospital for Tropical Diseases Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam
Trials 12:25. 2011.... - Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern SenegalPhilippe Brasseur
Institut de recherche pour le developpement IRD, UMR 198, Rue Wagane Diouf Georges Pompidou, Dakar, Senegal
Malar J 10:203. 2011..Since 2000, there has been a staggered deployment of artesunate-amodiaquine after parasitological confirmation; this was adopted nationally in 2006... - The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnershipCatherine Lacaze
Ellipse Pharmaceuticals, Pessac, France
Malar J 10:142. 2011.... - Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan AfricaFelista Mwingira
Dares Salaam University College of Education P O BOX 2329, Dar es Salaam, Tanzania
Malar J 10:79. 2011..This study presents the genetic diversity of P. falciparum msp1, msp2 and glurp markers in selected sub-Saharan Africa countries with varying levels of endemicity namely Malawi, Tanzania, Uganda, Burkina Faso and São Tomé... - The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malariaSue J Lee
Mahidol Oxford Tropical Medicine Research Unit MORU, Mahidol University, Faculty of Tropical Medicine, 3rd Floor, 60th Anniversary Chalermprakiat Building, 420 6 Ratchawithi Rd, Ratchathewi District, Bangkok 10400, Thailand
Malar J 7:149. 2008..Anaemia is assessed either by measurement of the haematocrit or the haemoglobin concentration. For comparisons across studies, it is often necessary to derive one measure from the other... - World Antimalarial Resistance Network (WARN) IV: clinical pharmacologyKaren I Barnes
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Malar J 6:122. 2007.... - The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparumSodiomon B Sirima
Centre National de Recherche et de Formation sur le Paludisme CNRFP, BP 2208, Ouagadougou, Burkina Faso
Malar J 8:48. 2009..Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested... - Ensuring sustained ACT production and reliable artemisinin supplyJean Marie Kindermans
AEDES Foundation, 34, rue Joseph II, 1000, Brussels, Belgium
Malar J 6:125. 2007..Production and cost data provided in this paper are based on an ongoing project (Artepal). Stability data are derived from a development project on rectal artesunate... - World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugsRic N Price
International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
Malar J 6:119. 2007..This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed... - Geometric least squares means ratios for the analysis of Plasmodium falciparum in vitro susceptibility to antimalarial drugsMichel Vaillant
Clinical Epidemiology and Public Health Unit, Centre for Health Studies, Centre de Recherche Publique CRP Santé, Luxembourg
Malar J 6:156. 2007..For antimalarial drugs, as well as for antibiotics, assessing changes in microbe susceptibility over time under drug pressure would help inform treatment policy decisions, but no standard statistical method exists as yet... - Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysisJulien Zwang
Shoklo Malaria Research Unit, Mae Sot, Thailand
Malar J 8:203. 2009..It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an evidence-based drug policy... - Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in ColombiaLyda Osorio
Internacional Centre for Medical Research and Training CIDEIM Avenida 1N 3 03, Cali, Colombia
Malar J 6:25. 2007..Artemisinin-based combination therapy (ACT) is being widely promoted as a strategy to counteract the increase in Plasmodium falciparum antimalarial drug resistance... - Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African childrenElizabeth A Ashley
Epicentre, Paris, France
Malar J 7:154. 2008..Use of different methods for assessing the efficacy of artemisinin-based combination antimalarial treatments (ACTs) will result in different estimates being reported, with implications for changes in treatment policy... - A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malariaStephane Picot
Malaria Research Unit, EA 4170, University Lyon 1, Faculty of Medicine, Lyon, France
Malar J 8:89. 2009..The purpose of this systematic review was to determine the risk of treatment failure associated with specific polymorphisms in the parasite genome or gene copy number... - Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs)Jean Marie Kindermans
AEDES Foundation, Brussels, Belgium
Malar J 6:91. 2007..There is no ideal method to quantify drug requirements for malaria. Morbidity data give uncertain estimations. This study uses drug consumption to provide elements to help estimate quantities and financial requirements of ACTs... - Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern SénégalPhilippe Brasseur
UR 077, IRD, Dakar, Senegal
Malar J 6:150. 2007..There are no data on the long term use of an artemisinin combination treatment in moderate or high transmission areas of Africa... - Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteersVisweswaran Navaratnam
National Center for Drug Research CRD, Universiti Sains Malaysia USM, 11800 Minden, Pulau Pinang, Penang, Malaysia
Eur J Clin Pharmacol 65:809-21. 2009..This study examines the bioavailability and tolerability of a fixed (200 mg artesunate + 540 mg amodiaquine) and loose (200 mg + 612 mg) combination with a 2x2 cross-over design in 24 healthy volunteers... 
Drug combinations for visceral leishmaniasisPiero L Olliaro
UNICEF UNPD World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
Curr Opin Infect Dis 23:595-602. 2010..Several attempts have been made to combine drugs for treating visceral leishmaniasis, but only recently have effective drugs become available and combinations been tested systematically...- Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, IndiaPiero Olliaro
UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
Trop Med Int Health 14:918-25. 2009..To assess the cost-effectiveness of current monotherapies and prospective combinations for treating visceral leishmaniasis (VL) in Bihar, India in terms of years of life lost (YLL) averted as well as deaths averted... - The global portfolio of new antimalarial medicines under developmentP Olliaro
UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
Clin Pharmacol Ther 85:584-95. 2009..The portfolio is discussed in terms of the novelty of the new molecules and their potential health impact in terms of addressing the requirements for the control and eventual eradication of malaria... - Standardised versus actual white cell counts in estimating thick film parasitaemia in African children under fivePiero Olliaro
UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
Trop Med Int Health 16:551-4. 2011.... - Pharmacokinetics of artesunate after single oral administration to ratsP L Olliaro
UNPD World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CDS, World Health Organization, 20, avenue AppiaCH 1211 Geneva 27, Switzerland
BMC Pharmacol 1:12. 2001..In order to study the absorption phase of the kinetics of artesunate following oral administration in rats, samples were collected at baseline, and then 0.5, 2, 5, 10, 15, 30, 45, 60 and 120 minutes after a single dose of 150 mg... - Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan AfricaPiero Olliaro
United Nations Children s Fund United Nations Development Program World Bank World Health Organization Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
Am J Trop Med Hyg 85:619-25. 2011..These analyses provides information on hematologic variations caused by malaria... - Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, IndiaP Olliaro
UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
Trop Med Int Health 14:88-92. 2009..To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India... - Drug resistance hampers our capacity to roll back malariaPiero Olliaro
United Nations International Children s Emergency Fund United Nations Development Programme World Bank World Health Organization Special Programme on Research and Training in Tropical Diseases, Geneva, Switzerland
Clin Infect Dis 41:S247-57. 2005..The current situation favors the development of sensible strategies to restrain resistance... - Controlling malaria: challenges and solutionsP Olliaro
UNDP World Bank World Health Organization Special Program for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
Trop Med Int Health 6:922-7. 2001..The paper describes a multilateral, multidisciplinary research project on artemisinin-based combination therapy, which offers a new and potentially highly effective way to prevent or retard the development of drug resistance... - Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004Piero L Olliaro
UNICEF UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, WHO, Geneva, Switzerland
Lancet Infect Dis 5:763-74. 2005..India, Bangladesh, and Nepal agreed recently to undertake measures towards the elimination of visceral leishmaniasis. The lessons learnt in Bihar could help inform policy decisions both regionally and elsewhere... - Antimalarial compounds: from bench to bedsidePiero L Olliaro
UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
J Exp Biol 206:3753-9. 2003..This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin-based combinations to those that need them most... - Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatmentPiero Olliaro
UNICEF UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases TDR, Geneva, Switzerland
Trop Med Int Health 13:83-90. 2008..Current guidelines recommend treatment only when patients develop symptoms or at the end of follow-up. We wanted to assess prospectively the probability of becoming symptomatic and the risks of this practice... - [Treatment of malaria: outlook]Piero Olliaro
Bull Acad Natl Med 191:1285-92. 2007..The development and deployment of new products is both lengthy and complex... - Editorial commentary: mortality associated with severe Plasmodium falciparum malaria increases with agePiero Olliaro
United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
Clin Infect Dis 47:158-60. 2008 - Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural SenegalPiero L Olliaro
UNICEF UNDP WB WHO Special Programme for Research and Training in Tropical Diseases TDR, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
Malar J 7:234. 2008..Indicators of implementation and effects of IPTp-SP were collected in a rural clinic in Southern Senegal... - Possible modes of action of the artemisinin-type compoundsP L Olliaro
UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, CDS Cluster, 20, Avenue Appia, CH 1211, Geneva, Switzerland
Trends Parasitol 17:122-6. 2001..However, uncertainties remain as to how they act on the parasite and cause toxicity. In this review, we summarize current ideas... - What role can public health institutions play in drug development for the poor? A case study of artesunateM Gomes
Special Programme for Research and Training in Tropical Diseases, TDR WHO, Geneva, Switzerland
Med Trop (Mars) 58:97-100. 1998..In essence, each and every player has rallied in the challenge to reduce the discrepancy between need and availability of a drug that can has the potential to reduce mortality form the disease... - Mode of action and mechanisms of resistance for antimalarial drugsP Olliaro
World Health Organization, Communicable Diseases Cluster CDS, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases TDR, CH 1211 27, Geneva, Switzerland
Pharmacol Ther 89:207-19. 2001..The use of closely related compounds has promoted the spread of multidrug resistant parasites. This review intends to collate contemporary knowledge, and also to highlight conflicting views on unresolved issues... - Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trialM F Gomes
UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
Lancet 373:557-66. 2009..We investigated whether this intervention reduced mortality and permanent disability... - Status of antimalarial drugs under developmentP L Olliaro
Steering Committee on Drugs for Malaria, UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
Bull World Health Organ 73:565-71. 1995..Some of these drugs may become available in the next few years. It is therefore essential to find mechanisms to ensure that they are made available at an affordable price to the populations that really need them... - Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malariaWalter R J Taylor
Special Programme for Research and Training in Tropical Diseases, United Nations Children's Fund/World Bank/United Nations Development Programme/World Health Organization, Geneva, Switzerland
Bull World Health Organ 84:956-64. 2006..CONCLUSION: The proposed method to use weight-for-age reference data from countries where malaria is endemic is a useful tool for designing age-based dosing regimens for antimalarial drugs for drug registration and field use... - Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatmentKefas Mugittu
Ifakara Health Research and Development Centre, Ifakara, Tanzania
Trop Med Int Health 12:219-23. 2007..2%)] and 14 [24/51 (47.1%)]. These results impact significantly on resistance monitoring and point to the value of genotyping all recurrent infections in antimalarial trials... - Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDRWalter R Taylor
UNDP World Bank World Health Organization Special Programme for Research and Training in Tropical Diseases TDR, Geneva, Switzerland
J Vector Borne Dis 40:65-72. 2003..They were high for amodiaquine-artesunate, variable for sulfadoxine/pyrimethamine-artesunate, and poor for chloroquine-artesunate... - Miltefosine in visceral leishmaniasisPiero L Olliaro
Lancet Infect Dis 3:70. 2003